Of note, mogamulizumab treatment has also shown to efficiently deplete Treg cells in patients with ATLL and CTCLs [173] and to increase tumor-specific CD8+ T cells in the blood of patients with ATLL [174,202]. Here, CD8A is linked to adult T-cell leukemia/lymphoma.